文献速递神经肿瘤

基于dCas9/CRISPR的O-6-甲基鸟嘌呤-DNA甲基转移酶甲基化增强恶性胶质瘤对替莫唑胺的化疗敏感性

dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma.
PubMed 文献 · J Neurooncol · 2024-01-15

本研究通过慢病毒介导将dCas9/DNMT3A催化结构域递送至LN18胶质瘤细胞,靶向MGMT启动子及增强子区域实现甲基化,观察到MGMT下调及体外生存实验中胶质瘤化疗敏感性增强,脱靶效应极小。作者认为dCas9/CRISPR是可行的表观遗传编辑方法,为恶性胶质瘤的CRISPR应用提供了初步原理验证。

要点

  • dCas9/DNMT3A催化结构域可实现MGMT启动子、增强子、DMR及MSP区域特定CpG簇的靶向甲基化。
  • 靶向甲基化导致MGMT下调并在体外生存实验中增强胶质瘤化疗敏感性,脱靶效应极小。
  • 作者认为该研究为恶性胶质瘤的CRISPR表观遗传编辑应用提供了初步原理验证。

核心结论

  • dCas9/CRISPR利用DNMT3A催化结构域是可行的表观遗传编辑方法。
  • 本研究为CRISPR技术在恶性胶质瘤中的应用提供了初步原理验证,为后续转化研究奠定基础,并对未来基于表观遗传编辑的临床应用具有意义。

研究设计与样本

  • 通过慢病毒介导将dCas9-CRISPR技术递送至LN18胶质瘤细胞,靶向MGMT启动子及增强子区域,由甲基化酶DNMT3A催化结构域介导甲基化。
  • 在包含差异甲基化区域(DMR1、DMR2)及用于临床评估MGMT甲基化状态的甲基化特异性PCR(MSP)区域的克隆水平检查甲基化模式。
  • 通过Illumina 850K甲基化芯片平台和bulk RNA-Seq分析进行dCas9/CRISPR基于甲基化的基因组和转录组效应的相关性研究。

主要发现

  • 使用dCas9/DNMT3A催化结构域在启动子、增强子、DMRs及MSP区域附近的特定CpG簇实现了靶向MGMT甲基化。
  • 观察到MGMT下调,并在体外生存实验中增强胶质瘤化疗敏感性,脱靶效应极小。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Malignant glioma carries a poor prognosis despite current therapeutic modalities. Standard of care therapy consists of surgical resection, fractionated radiotherapy concurrently administered with temozolomide (TMZ), a DNA-alkylating chemotherapeutic agent, followed by adjuvant TMZ. O-6-methylguanine-DNA methyltransferase (MGMT), a DNA repair enzyme, removes alkylated lesions from tumor DNA, thereby promoting chemoresistance. MGMT promoter methylation status predicts responsiveness to TMZ; patients harboring unmethylated MGMT (~60% of glioblastoma) have a poorer prognosis with limited treatment benefits from TMZ. METHODS: Via lentiviral-mediated delivery into LN18 glioma cells, we employed deactivated Cas9-CRISPR technology to target the MGMT promoter and enhancer regions for methylation, as mediated by the catalytic domain of the methylation enzyme DNMT3A. Methylation patterns were examined at a clonal level in regions containing Differentially Methylation Regions (DMR1, DMR2) and the Methylation Specific PCR (MSP) region used for clinical assessment of MGMT methylation status. Correlative studies of genomic and transcriptomic effects of dCas9/CRISPR-based methylation were performed via Illumina 850K methylation array platform and bulk RNA-Seq analysis. RESULTS: We used the dCas9/DNMT3A catalytic domain to achieve targeted MGMT methylation at specific CpG clusters in the vicinity of promoter, enhancer, DMRs and MSP regions. Consequently, we observed MGMT downregulation and enhanced glioma chemosensitivity in survival assays in vitro, with minimal off-target effects. CONCLUSION: dCas9/CRISPR is a viable method of epigenetic editing, using the DNMT3A catalytic domain. This study provides initial proof-of-principle for CRISPR technology applications in malignant glioma, laying groundwork for subsequent translational studies, with implications for future epigenetic editing-based clinical applications.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Zapanta Rinonos S, Li T, Pianka ST, et al. dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma. J Neurooncol. 2024. PMID: 38224404. doi:10.1007/s11060-023-04531-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。